Foundayo (ATTAIN-1 trial) was far larger, with 3,127 adults in the same broad population
It keeps shots or pills, injection sites, food, protein, fiber, water, symptoms, weight, progress photos, medication context, Journey Cards, and daily support in one GLP-1-specific app
They say the OSA market is vast and underserved, thereby leaving plenty of market share for ResMed to gain regardless of the success of Ozempic and other GLP-1s in reducing obesity
The key is progressive loading: gradually increasing the challenge over time so the muscles continue to receive a growth and maintenance stimulus
The treatments are completely different, so accurate diagnosis matters
What is the difference between GHK-Cu and Argireline